The Global Health Investment Fund (GHIF) provided a $6 million loan to Atomo Diagnostics to support the scale-up of production operations and the expansion of commercial activities related to the AtomoRapid rapid diagnostic test platform. Funds will also be used to commercialize a self-test solution for HIV and other infectious diseases.

Structured by JPMorgan Chase and the Bill & Melinda Gates Foundation, with founding support from Grand Challenges Canada, KfW and SIDA, GHIF focuses its investments in companies addressing key global health challenges.

Curt LaBelle, MD, president of GHIF, said, “We are committed to financing initiatives and technologies that can significantly benefit global health. We believe the company’s unique and innovative rapid test solutions support point-of-care testing across a variety of settings and have many exciting applications in both the developing world and developed markets.”

As part of the collaborative funding agreement, GHIF and Atomo have made global access commitments to support and facilitate the launch and commercialization of Atomo’s professional use and self-test products in low and middle-income countries to ensure that they achieve the greatest possible global impact.